
@edilyticsi
iAccount based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Precision analytics for genome editing. Creators of CRISPResso2.
Joined February 2019
- Tweets254
- Following128
- Followers93
- Likes14
Thanks for using CRISPResso!
Scientific sharing fuels progress. Our friends at @Edilytics developed CRISPResso, an open-source CRISPR analysis tool built for researchers.
Together with OpenCRISPR-1, the future of customizable gene editing is more accessible than ever.
Check it out: edilytics.com/#crispresso
We are thrilled to be a part of @BioUtah!
🎉 Welcome, @Edilytics, to @BioUtah!
Their flagship product, CRISPResso, is the industry standard for analyzing genome editing events from NGS data, supporting diverse editing modalities with 1,650+ citations in academia & industry.
🔗 Learn more: edilytics.com
We are excited to attend @CSHL's CRISPR Frontiers conference next week. Let us know if you are going and we can talk all things genome editing analysis!
Congratulations to @CRISPRTX and @VertexPharma for UK approval of Casgevy to treat sickle-cell disease and β-thalassaemia.
Hope to continue to see more therapies brought closer to the clinic!
nature.com/articles/d41586-0…
Excellent talk @grunewaju! #esgct
(Thanks for using CRISPResso in your slides and work)
Happy #WorldCRISPRDay! To celebrate we would like to announce the launch of crispresso.com.
Join us in celebration by analyzing your #CRISPR experiment, happy analyzing!
Our team is excited to be at the @ESGCT congress next week! If you are going we would love to meet you in person, feel free to reach out so that we can connect.
Fascinating protocol from Changtian Pan @PCT71158462 & Yiping Qi constructing CRISPR-Combo systems for speed breeding of genome-edited plants. Thanks for using #CRISPResso in your analysis!
nature.com/articles/s41596-0…
Congratulations to Bestas et al. on their paper illustrating a new nuclease with lower off-targets and translocations.
Thanks for using CRISPResso! nature.com/articles/s41467-0…
Congratulations to Alex Reed, Benjamin Cravatt, @jfernandobazan, et al. on their groundbreaking paper utilizing #CRISPR technology to show the role of TMEM164 in ferroptosis.
Thanks for using #crispresso2
nature.com/articles/s41589-0…
Congratulations to Mohr, Damas, Gudmand-Høyer, et al. on their groundbreaking @ACSSynBio paper utilizing #CRISPR technology for precise genetic engineering.
Thank you for using #crispresso2!
pubs.acs.org/doi/10.1021/acs…
Congrats to Kaiqin She, Yi Liu, Qinyu Zhao, et al. on their recent paper on correcting mutations and phenotypes in retinal degenerative mice using split prime editing.
Thanks for using #crispresso2
doi.org/10.1038/s41392-022-0…
Congrats to Fuminori Tanihara, Maki Hiratat, et al. on their recent paper using electroporation and #CRISPR to cause an INS point mutation in pigs!
Thanks for using #crispresso2!
doi.org/10.3389/fcell.2023.8…
Congrats to @kaisa_pakari @WittbrodtLab @_ThomThum_ et al. on their recent paper on de novo PAM generation to reach initially inaccessible target sites for base editing .
Thanks for using #crispresso2
journals.biologists.com/dev/…
Congrats to Li, et al. on their recent paper developing prime editing.
Thanks for using #crispresso2!
doi.org/10.1038/s41467-023-3…
Congrats to Jin, et al. on their recent paper on how to circumvent barriers to in vivo #CRISPR use.
Thanks for using #crispresso2!
genomebiology.biomedcentral.…
Congrats to Liao, Chen, Hsiao, Jiang, et al. on their recent paper using #CRISPR base editing to potentially treat inherited monogenic blood disorders!
Thanks for using #crispresso2!
doi.org/10.1038/s41467-022-3…
Congrats to @nicopmat #AhmedAllam et al. on their recent paper using high-throughput screen to analyze #primeediting outcomes.
Thanks for using #crispresso2
doi.org/10.1038/s41587-022-0…
Edilytics retweeted
We're leading the next generation of gene editing and are excited to make our Twitter debut. Follow us to stay in the loop on all things $PRME.




